Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06226558
Other study ID # 75N94021D00018-75N94023F00001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date February 1, 2024
Est. completion date October 1, 2026

Study information

Verified date April 2024
Source Stony Brook University
Contact Andrew Handel, MD
Phone 631-444-7692
Email Andrew.handel@stonybrookmedicine.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen. By following all infants who screen positive, we will learn important information about the range of symptoms caused by congenital CMV, from those babies with more severe findings to those with no symptoms. In particular, our study will provide new information about many facets of congenital CMV, including: - Developmental, hearing, neurologic, and vision outcomes - The spectrum and timing of symptoms - The impact congenital CMV has on the baby and its family - How many babies are infected with congenital CMV in New York State How antiviral medications and other interventions impact outcomes of children with congenital CMV Throughout the duration of the study, children will undergo routine developmental and hearing assessments, which will assist with early diagnosis of any infection complications. Any child found to have a neurodevelopmental, hearing, or vision abnormality will be referred for appropriate evaluation and treatment. Families will also be asked to complete periodic surveys about their experience with congenital CMV, both as a medical diagnosis and as it affects their day-to-day activities.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date October 1, 2026
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 0 Days to 1 Year
Eligibility Inclusion Criteria: - Neonates born in New York State during cCMV NBS Pilot Program (September 27, 2023 - October 1, 2024) - cCMV evaluation provided by a designated NYS cCMV clinical referral site - Family willing and able to complete all study procedures - Study participants meet criteria for one of the following four categories: - 1. Category 1 (Confirmed cCMV identified by NBS Program): cCMV NYS newborn screen positive AND cCMV confirmatory test positive - 2. Category 2 (Confirmed cCMV not identified by NBS Program): cCMV NYS newborn screen negative AND cCMV confirmatory test positive - 3. Category 3 (False-positive cCMV screen): cCMV NYS newborn screen positive AND negative cCMV confirmatory test - 4. Category 4 (Premature infants with confirmed CMV infection on late positive NBS): Infant born prior to 37 weeks gestation AND cCMV positive on any NYS newborn screen collected prior to 44 weeks gestational age AND Positive cCMV confirmatory test obtained within 14 days of a positive NBS Exclusion Criteria: - Neonate whose parents refuse participation in the long-term follow-up study

Study Design


Locations

Country Name City State
United States Stony Brook Children's Hospital Stony Brook New York

Sponsors (2)

Lead Sponsor Collaborator
Stony Brook University Frontier Science & Technology Research Foundation, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (3)

Fowler KB, Boppana SB. Congenital cytomegalovirus infection. Semin Perinatol. 2018 Apr;42(3):149-154. doi: 10.1053/j.semperi.2018.02.002. Epub 2018 Mar 2. — View Citation

Pesch MH, Saunders NA, Abdelnabi S. Cytomegalovirus Infection in Pregnancy: Prevention, Presentation, Management and Neonatal Outcomes. J Midwifery Womens Health. 2021 May;66(3):397-402. doi: 10.1111/jmwh.13228. Epub 2021 May 24. — View Citation

Rawlinson WD, Boppana SB, Fowler KB, Kimberlin DW, Lazzarotto T, Alain S, Daly K, Doutre S, Gibson L, Giles ML, Greenlee J, Hamilton ST, Harrison GJ, Hui L, Jones CA, Palasanthiran P, Schleiss MR, Shand AW, van Zuylen WJ. Congenital cytomegalovirus infection in pregnancy and the neonate: consensus recommendations for prevention, diagnosis, and therapy. Lancet Infect Dis. 2017 Jun;17(6):e177-e188. doi: 10.1016/S1473-3099(17)30143-3. Epub 2017 Mar 11. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Congenital CMV infection rate To determine the rate of confirmed congenital CMV in a statewide cohort Study initiation to 1 year time point
Secondary cCMV neonatal sensorineural hearing loss Rate of neonatal sensorineural hearing decibel loss as determined by Auditory Brainstem Response testing Through 4 weeks old
Secondary cCMV antiviral therapy utilization Frequency of antiviral prescriptions 2 years
Secondary cCMV acquired sensorineural hearing loss Rate of acquired sensorineural hearing decibel loss as determined by Auditory Brainstem Response testing 2 years
Secondary cCMV neurodevelopmental outcomes Neurodevelopmental abnormalities as measured by Bayley Scales of Infant & Toddler Development-III.
The Bayley-III includes Cognitive, Language, Motor, Social-Emotional, and Adaptive Behavior scales. Age-normalized scores are calculated for each domain, with a lower score indicating greater impairment.
2 years
Secondary cCMV-related quality of life Quality of life score as determined by the Pediatric Quality of Life Inventory Infant Scales (PedsQL).
The PedsQL Infant Scales consist of parent-reported psychosocial health symptoms. A higher score on the PedsQL indicates more severe psychosocial health symptoms.
2 years
See also
  Status Clinical Trial Phase
Completed NCT00023036 - Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
Completed NCT03746613 - Clinal Evaluation of Navigation Based Functional Ear Surgery Using Image Guided and Robotically Assisted Techniques N/A
Recruiting NCT05568329 - Appreciation for Music Processed by Hearing Aids N/A
Withdrawn NCT05061758 - A Trial of LY3056480 in Patients With SNLH Phase 2
Completed NCT01434446 - The Effect of Sound Stimulation on Hearing Ability N/A
Completed NCT03212924 - Listening Effort in Cochlear Implant Users N/A
Recruiting NCT06053190 - Effects of Clear Speech on Listening Effort and Memory in Sentence Processing N/A
Completed NCT03718975 - Quality Control of CE-Certified Phonak Hearing Aids - 2018_28 N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1
Recruiting NCT04102215 - The Efficacy of a Minimally Invasive Direct Cochlear Access Via the HEARO Procedure N/A
Recruiting NCT04108598 - The SeaSHeL National Prospective Cohort Study
Active, not recruiting NCT04750642 - Cochlear Implant With Dexamethasone Eluting Electrode Array N/A
Completed NCT04120116 - FX-322 in Adults With Stable Sensorineural Hearing Loss Phase 2
Recruiting NCT06223724 - Status Telemetry for Cochlear Implantations
Completed NCT02005822 - Congenital Cytomegalovirus: Efficacy of Antiviral Treatment Phase 3
Suspended NCT02616172 - Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss Phase 1/Phase 2
Completed NCT02259595 - Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC Phase 1
Unknown status NCT01902914 - Effectiveness of P02 Digital Hearing Aids Phase 1/Phase 2
Completed NCT00589511 - Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study N/A
Completed NCT03288753 - Comparison Between Neuro 1 and Neuro 2 Cochlear Implant Speech Processors N/A

External Links